<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251952</url>
  </required_header>
  <id_info>
    <org_study_id>WSU 2010-039</org_study_id>
    <nct_id>NCT01251952</nct_id>
  </id_info>
  <brief_title>Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation</brief_title>
  <official_title>Phase I Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to determine the feasibility and safety of giving two doses
      of denileukin diftitox (DD) at days 0 and 21 post autologous stem cell transplantation in a
      dose escalation fashion. Secondary goals include evaluating the the effect of DD on the
      number and percentage of T-regs in the peripheral blood post transplant at each dose level,
      the effect of DD on T cell (CD4/CD8) reconstitution post transplant at each dose level and
      determining the time to engraftment: absolute neutrophil count (&gt;0.5 x 10^9/L for 3
      consecutive days), and platelet (&gt;20X 10^9/L for 3 consecutive days).

      The hypothesis for the study is based on the ability of DD to deplete T-regs and subsequently
      enhance the immune reconstitution and reverse post transplant lymphopenia. This may
      indirectly enhance the efficacy of autologous transplantation and reduce disease relapse.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Drug unavailable
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Toxicities of Giving Two Doses of Ontak at Days 0 and 21 Post Autologous Stem Cell Transplantation in a Dose Escalation Fashion.</measure>
    <time_frame>Up to 21 days post transplant</time_frame>
    <description>After drug infusion, participants will be closely monitored for at least 4 hours for side effects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Effect of Ontak on the Number and Percentage of Regulatory T Cells in the Peripheral Blood Post Transplant at Each Dose Level.</measure>
    <time_frame>days 0 and 21 post autologous stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Effect of Ontak on T Cell CD4/CD8 Reconstitution Post Transplant at Each Dose.</measure>
    <time_frame>days 0 and 21 post autologous stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Effect of Ontak on Engraftment of Neutrophils and Platelets Post Transplant at Each Dose.</measure>
    <time_frame>days 0 and 21 post autologous stem cell transplantation</time_frame>
    <description>During hospitalization stay (approximately 2 weeks), participants will receive injections of G-CSF on a daily basis starting on Day 6 and ending when white blood cells have engrafted. Participants usually remain hospitalized until engraftment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Denileukin Diftitox (Ontak)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denileukin Diftitox (Ontak)</intervention_name>
    <description>After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.
Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360.</description>
    <arm_group_label>Denileukin Diftitox (Ontak)</arm_group_label>
    <other_name>OntakÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients age &gt; =18 who have been diagnosed with Multiple Myeloma and are scheduled for
        autologous peripheral blood hematopoietic stem cell transplant (AHSCT) will be screened for
        eligibility.

        Patients must fulfill all of the following inclusion criteria to be eligible for this
        study:

          1. Diagnosis of Multiple Myeloma

          2. Age &gt;=18 and no more than 70 years.

          3. Able to understand and sign a consent form.

          4. Can collect peripheral blood stem cells with a CD34+ cell dose of at least 5.0 x
             106/kg. The CD34 molecule is a Cluster of Differentiation molecule present on
             hematopoietic stem cells.

          5. Conditioning regimen to be high dose Melphalan at a dose of 200mg/m2.

          6. Karnofsky Performance Score (KPS) &gt;60 or ECOG (Eastern Cooperative Oncology Group)
             performance status &lt;=2

          7. Kidney function:Creatinine &lt;2.0 mg/dl or creatinine clearance &gt;50 ml/min

          8. Heart function: Ejection fraction &gt;45%

          9. Liver function tests :Serum bilirubin, alanine aminotransferase (ALT), aspartate
             aminotransferase (AST) less than 3 X upper limit of normal

         10. Lung function tests: Forced Vital Capacity (FVC), Forced Expiratory Volume in One
             Second (FEV1) or Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) &gt;45%
             predicted

        Exclusion Criteria:

          1. Age &lt;18 years or &gt; 70 years

          2. Previous exposure to denileukin diftitox.

          3. Patients with documented uncontrolled central nervous system (CNS) disease.

          4. Previous AHSCT.

          5. Significant organ dysfunction deemed to be inappropriate for autologous
             transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaid Al-Kadhimi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <results_first_submitted>October 25, 2013</results_first_submitted>
  <results_first_submitted_qc>October 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2013</results_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Zaid Al-Kadhimi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denileukin diftitox</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Cancer center clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Denileukin Diftitox (Ontak)</title>
          <description>Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.
Denileukin Diftitox (Ontak) : After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.
Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Denileukin Diftitox (Ontak)</title>
          <description>Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.
Denileukin Diftitox (Ontak) : After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.
Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assess Toxicities of Giving Two Doses of Ontak at Days 0 and 21 Post Autologous Stem Cell Transplantation in a Dose Escalation Fashion.</title>
        <description>After drug infusion, participants will be closely monitored for at least 4 hours for side effects</description>
        <time_frame>Up to 21 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denileukin Diftitox (Ontak)</title>
            <description>Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.
Denileukin Diftitox (Ontak) : After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.
Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Toxicities of Giving Two Doses of Ontak at Days 0 and 21 Post Autologous Stem Cell Transplantation in a Dose Escalation Fashion.</title>
          <description>After drug infusion, participants will be closely monitored for at least 4 hours for side effects</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Effect of Ontak on the Number and Percentage of Regulatory T Cells in the Peripheral Blood Post Transplant at Each Dose Level.</title>
        <time_frame>days 0 and 21 post autologous stem cell transplantation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Effect of Ontak on T Cell CD4/CD8 Reconstitution Post Transplant at Each Dose.</title>
        <time_frame>days 0 and 21 post autologous stem cell transplantation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Effect of Ontak on Engraftment of Neutrophils and Platelets Post Transplant at Each Dose.</title>
        <description>During hospitalization stay (approximately 2 weeks), participants will receive injections of G-CSF on a daily basis starting on Day 6 and ending when white blood cells have engrafted. Participants usually remain hospitalized until engraftment.</description>
        <time_frame>days 0 and 21 post autologous stem cell transplantation</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Denileukin Diftitox (Ontak)</title>
          <description>Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.
Denileukin Diftitox (Ontak) : After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.
Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Streptococcus in urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Low BUN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Analysis was not completed due to the small number of patients accrued and drugs were unavailable.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Zaid Al-Kadhimi, M.D.</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>(313) 576-8022</phone>
      <email>alkadhiz@karmanos.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

